Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Continuous glucose monitors — the tiny sensors once reserved for people with diabetes — are now appearing on the arms of ...

We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.’s share was trading at $65.41 as of October 15th.

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now. On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving ...

A powerful new AI tool called Diag2Diag is revolutionizing fusion research by filling in missing plasma data with synthetic yet highly detailed information. Developed by Princeton scientists and ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Biolinq is led by CEO Rich Yang, a former manager at Dexcom and Medtronic. The company was co-founded by Chief Technology Officer Jared Tangney, who has a background in micro-array sensor research and ...